Scalper1 News
BY Biogen beat second-quarter earnings estimates Friday, but the big-cap biotech’s stock crashed on weak sales, sharply lower guidance and reported failure in a clinical trial. Biogen’s (BIIB) earnings, excluding one-time items, rose 21% vs. a year earlier to $4.22 a share, beating analysts’ views by 12 cents. Revenue climbed 7% to $2.6 billion, about $120 million short of consensus. Biogen slashed its full-year revenue guidance to Scalper1 News
Scalper1 News